Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cysteine Hydrochloride

FDA-approved product (injectable, injection), marketed as Cysteine Hydrochloride, Elcys, Nouress.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Cysteine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Liver disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

Anti-infective classification
Neither a WHO ATC code nor an FDA pharmacologic class was found for it, so whether it is already an antimicrobial is not established. It needs review and is not counted as a repurposing candidate.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Cysteine Hydrochloride, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA9.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli8.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae8.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis17.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cysteine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cysteine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Open Label Study: Treatment of ALS Fatigue With PolyMVA

    NCT04557410 · start 2020-09-23

    Registered record
    Registry ID
    NCT04557410
    Conditions
    Amyotrophic Lateral Sclerosis
    Interventions
    PolyMVA
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-09-23
    Completion
    2021-05-25
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyotrophic Lateral Sclerosis
    InterventionPolyMVA
    PhasePhase 1
    Registry statusCompleted

  • A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients

    NCT04458298 · start 2020-08-11

    Registered record
    Registry ID
    NCT04458298
    Conditions
    COVID-19
    Interventions
    OP-101; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2020-08-11
    Completion
    2022-08-12
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionOP-101; Placebo
    PhasePhase 2
    Registry statusTerminated

  • A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Single and Multiple Intravenous Doses of N-acetylcysteine (NAC) in Chinese Healthy Volunteers

    NCT03881163 · start 2019-11-11

    Registered record
    Registry ID
    NCT03881163
    Conditions
    Respiratory Tract Disorders
    Interventions
    N-acetylcysteine (NAC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-11-11
    Completion
    2020-01-18
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRespiratory Tract Disorders
    InterventionN-acetylcysteine (NAC)
    PhasePhase 1
    Registry statusCompleted

  • Pilon Fracture With Intra-articular Injection of N-Acetylcysteine (Pilon NAC)

    NCT03652753 · start 2019-01-01

    Registered record
    Registry ID
    NCT03652753
    Conditions
    Pilon Fracture
    Interventions
    N-acetylcysteine; Saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2019-01-01
    Completion
    2026-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPilon Fracture
    InterventionN-acetylcysteine; Saline
    PhasePhase 4
    Registry statusRecruiting

  • Inpatient Clinical Trial of NAC

    NCT03581084 · start 2018-07-06

    Registered record
    Registry ID
    NCT03581084
    Conditions
    Asthma
    Interventions
    N-acetylcysteine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2018-07-06
    Completion
    2018-10-06
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionN-acetylcysteine
    PhasePhase 4
    Registry statusTerminated

  • A Combined SAD and MAD Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of IFB-088

    NCT03610334 · start 2018-06-21

    Registered record
    Registry ID
    NCT03610334
    Conditions
    Healthy Volunteers
    Interventions
    IFB-088 (2.5-60.0mg) oral capsule; Placebo (2.5-60.mg) oral capsule; IFB-088 (15.0-50.0mg) oral capsule; Placebo oral (15.0-50.0mg) capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-06-21
    Completion
    2019-12-16
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionIFB-088 (2.5-60.0mg) oral capsule; Placebo (2.5-60.mg) oral capsule; IFB-088 (15.0-50.0mg) oral capsule; Placebo oral (15.0-50.0mg) capsule
    PhasePhase 1
    Registry statusCompleted

  • Dynamic Changes in the Levels of sCD62L and SPARC in Chronic Myeloid Leukemia Patients During Imatinib Treatment

    NCT05387330 · start 2018-04-01

    Registered record
    Registry ID
    NCT05387330
    Conditions
    Chronic Myeloid Leukemia
    Interventions
    ELISA kit
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-04-01
    Completion
    2021-12-28
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukemia
    InterventionELISA kit
    PhaseNot recorded
    Registry statusCompleted

  • N-Acetylcysteine and L-carnitine in Pcos

    NCT03164421 · start 2017-01

    Registered record
    Registry ID
    NCT03164421
    Conditions
    PCOS
    Interventions
    N-Acetylcysteine; L-carnitine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-01
    Completion
    2018-07
    Enrolment
    164

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPCOS
    InterventionN-Acetylcysteine; L-carnitine
    PhasePhase 2
    Registry statusCompleted

  • A Study of Oxidative Pathways in MS Fatigue

    NCT02804594 · start 2016-10-01

    Registered record
    Registry ID
    NCT02804594
    Conditions
    Progressive Multiple Sclerosis; Fatigue
    Interventions
    N-acetyl cysteine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-10-01
    Completion
    2018-06-01
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProgressive Multiple Sclerosis; Fatigue
    InterventionN-acetyl cysteine; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Effect of N-Acetylcysteine on Autologous Fat Graft Survival

    NCT02788292 · start 2016-08-15

    Registered record
    Registry ID
    NCT02788292
    Conditions
    Adipose Tissue Atrophy; Deformity of Reconstructed Breast; Graft Loss
    Interventions
    Acetylcysteine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2016-08-15
    Completion
    2020-11-16
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdipose Tissue Atrophy; Deformity of Reconstructed Breast; Graft Loss
    InterventionAcetylcysteine
    PhasePhase 4
    Registry statusWithdrawn

  • The Effect of Acute Tryptophan Depletion (ATD) on Esophageal Sensitivity in Healthy Volunteers

    NCT03017768 · start 2016-06

    Registered record
    Registry ID
    NCT03017768
    Conditions
    Esophageal Sensitivity
    Interventions
    Acute tryptophan depletion; Placebo; Multimodal stimulation probe
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-06
    Completion
    2017-03-24
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEsophageal Sensitivity
    InterventionAcute tryptophan depletion; Placebo; Multimodal stimulation probe
    PhaseNot applicable
    Registry statusCompleted

  • NACOS - The Effect of N-acetylcystein for Depressive Symptoms in Patients Suffering From Bipolar Depression

    NCT02294591 · start 2014-11

    Registered record
    Registry ID
    NCT02294591
    Conditions
    Bipolar Disorder
    Interventions
    N-acetylcysteine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-11
    Completion
    2016-10
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    InterventionN-acetylcysteine; Placebo
    PhasePhase 2
    Registry statusCompleted

  • THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS

    NCT02241876 · start 2014-10

    Registered record
    Registry ID
    NCT02241876
    Conditions
    Head and Neck Neoplasms
    Interventions
    N-acetylcysteine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2014-10
    Completion
    Not recorded
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Neoplasms
    InterventionN-acetylcysteine
    PhasePhase 4
    Registry statusUnknown

  • Macrophage Markers, Soluble CD163 (sCD163) and Soluble CD206 (sCD206) in Paracetamol Overdose

    NCT03679442 · start 2014-09-08

    Registered record
    Registry ID
    NCT03679442
    Conditions
    Drug-Induced Acute Liver Injury
    Interventions
    N-acetylcysteine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-09-08
    Completion
    2017-02-18
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug-Induced Acute Liver Injury
    InterventionN-acetylcysteine
    PhasePhase 1
    Registry statusCompleted

  • Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease

    NCT02212678 · start 2014-09

    Registered record
    Registry ID
    NCT02212678
    Conditions
    Parkinson Disease
    Interventions
    N-acetylcysteine capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-09
    Completion
    2015-09
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionN-acetylcysteine capsule
    PhasePhase 2
    Registry statusCompleted